Mazaev A V, Suvorova L A, Barbakar' N G
Kardiologiia. 1984 Jul;24(7):62-6.
The article deals with the effect of the intravenous administration of streptodekase with heparin on the hemostatic system in patients with acute myocardial infarction. The data obtained are compared with the corresponding parameters in patients treated with native streptokinase. The advantages of the new thrombolytic drug over ordinary streptokinase are shown: a one-time administration of the whole therapeutic dose of streptodekase allows a significant simplification of the thrombolytic therapy scheme; streptodekase induces prolonged activation of fibrinolysis (up to 5-7 days) without any signs of its subsequent depression and with the minimum inhibition of blood coagulation. The specific selective influence of streptodekase on the fibrinolytic system helps to obviate hemorrhagic and thromboembolic complications characteristic of native streptokinase. In addition, low antigenicity and toxicity of streptodekase ensure the absence of any allergic and adverse side-effects in patients treated with the drug.
本文探讨了静脉注射链道酶与肝素对急性心肌梗死患者止血系统的影响。将所获得的数据与使用天然链激酶治疗的患者的相应参数进行比较。结果显示，新型溶栓药物相对于普通链激酶具有以下优势：一次性给予链道酶全治疗剂量可显著简化溶栓治疗方案；链道酶可诱导纤维蛋白溶解的长期激活（长达5 - 7天），且无后续抑制迹象，同时对血液凝固的抑制作用最小。链道酶对纤维蛋白溶解系统的特异性选择性影响有助于避免天然链激酶特有的出血和血栓栓塞并发症。此外，链道酶的低抗原性和低毒性确保了使用该药物治疗的患者不会出现任何过敏和不良副作用。
